Lymphangiomyomatosis future or investigational therapies: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
|||
| Line 5: | Line 5: | ||
==Overview== | ==Overview== | ||
==Future or Investigational Therapies== | ==Future or Investigational Therapies== | ||
[[Doxycycline]] has been proposed as a treatment with minimal side-effects.<ref>{{cite journal | title=Doxycycline Treatment for Lymphangioleiomyomatosis with Urinary Monitoring for MMPs | author=Moses MA, Harper J, Folkman J | journal=New Engl J Med | year=2006 | volume=354 | pages=2621–22 | issue=24 }}</ref> | *[[Doxycycline]] has been proposed as a treatment with minimal side-effects.<ref>{{cite journal | title=Doxycycline Treatment for Lymphangioleiomyomatosis with Urinary Monitoring for MMPs | author=Moses MA, Harper J, Folkman J | journal=New Engl J Med | year=2006 | volume=354 | pages=2621–22 | issue=24 }}</ref> | ||
[[Sirolimus]] is being tested for the treatment of LAM. The MILES Trial (Multicenter International LAM Efficacy of Sirolimus Trial) is now underway. The first site, the University of Cincinnati, is open for enrollment. The National Institutes of Health will open enrollment soon. The MILES Trial is randomized, double-blinded, and placebo-controlled. The objective of the Trial is to determine if sirolimus has a beneficial effect on lung function in LAM patients. | *[[Sirolimus]] is being tested for the treatment of LAM. The MILES Trial (Multicenter International LAM Efficacy of Sirolimus Trial) is now underway. The first site, the University of Cincinnati, is open for enrollment. The National Institutes of Health will open enrollment soon. The MILES Trial is randomized, double-blinded, and placebo-controlled. The objective of the Trial is to determine if sirolimus has a beneficial effect on lung function in LAM patients. | ||
==References== | ==References== | ||
Revision as of 18:07, 14 September 2012
Template:Lymphangiomyomatosis Please help WikiDoc by adding content here. It's easy! Click here to learn about editing.
Overview
Future or Investigational Therapies
- Doxycycline has been proposed as a treatment with minimal side-effects.[1]
- Sirolimus is being tested for the treatment of LAM. The MILES Trial (Multicenter International LAM Efficacy of Sirolimus Trial) is now underway. The first site, the University of Cincinnati, is open for enrollment. The National Institutes of Health will open enrollment soon. The MILES Trial is randomized, double-blinded, and placebo-controlled. The objective of the Trial is to determine if sirolimus has a beneficial effect on lung function in LAM patients.
References
- ↑ Moses MA, Harper J, Folkman J (2006). "Doxycycline Treatment for Lymphangioleiomyomatosis with Urinary Monitoring for MMPs". New Engl J Med. 354 (24): 2621&ndash, 22.